The UCHL5 inhibitor b-AP15 overcomes cisplatin resistance via suppression of cancer stemness in urothelial carcinoma

Urothelial carcinoma (UC) comprises the majority of Model Kits bladder cancers.Standard platinum-based chemotherapy has a response rate of approximately 50%, but drug resistance develops after short-term treatment.Deubiquitinating (DUB) enzyme inhibitors increase protein polyubiquitination and endoplasmic reticulum (ER) stress, which might further

read more